Trial Profile

A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 04 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Isatuximab (Primary) ; Carfilzomib; Dexamethasone; Pomalidomide
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Acronyms IONA-MM
Sponsors Sanofi

Most Recent Events

08 Oct 2024 Status changed from recruiting to active, no longer recruiting.
01 Oct 2022 Results (n=112; Between 13 Aug 2020 and 22 Feb 2022) assessing baseline characteristics, treatment exposure, and safety for Isatuximab-treated relapsed and/or refractory multiple myeloma patients, published in the Clinical Lymphoma, Myeloma & Leukemia.
21 Mar 2022 Planned End Date changed from 1 Oct 2025 to 23 Feb 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com